Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers

Langmuir

Volumn 28, Issue 42, 2012, Pages 15015-15023

  Vehring, Reinhard ^a,b   Lechuga Ballesteros, David ^a   Joshi, Vidya ^a   Noga, Brian ^a   Dwivedi, Sarvajna K ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AERODYNAMIC DIAMETERS; CLINICAL DEVELOPMENT; DIHYDRATES; DOSE DELIVERY; DRUG EFFICACY; DRUG SUSPENSIONS; FINE PARTICLE FRACTIONS; FORMOTEROL FUMARATE; GLYCOPYRROLATE; METERED-DOSE INHALERS; MICRO-PARTICLES; POROUS PARTICLE; SUSPENSION STABILITY; TETRAFLUOROETHANE;

DRUG PRODUCTS; MICROCRYSTALS; PHOSPHOLIPIDS; POROUS MATERIALS; PROPELLANTS; SUSPENSIONS (FLUIDS);

DRUG DOSAGE;

ETHANOLAMINE DERIVATIVE; FLUORINATED HYDROCARBON; FORMOTEROL; FUMARIC ACID DERIVATIVE; GLYCOPYRRONIUM BROMIDE; MOMETASONE FUROATE; NORFLURANE; PHOSPHOLIPID; PREGNANE DERIVATIVE; WATER;

ARTICLE; ARTIFICIAL VENTILATION; CHEMISTRY; DRUG DELIVERY SYSTEM; METERED DOSE INHALER; PARTICLE SIZE; POROSITY; SOLUBILITY; SURFACE PROPERTY;

DRUG DELIVERY SYSTEMS; ETHANOLAMINES; FUMARATES; GLYCOPYRROLATE; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS; PARTICLE SIZE; PHOSPHOLIPIDS; POROSITY; PREGNADIENEDIOLS; RESPIRATORY THERAPY; SOLUBILITY; SURFACE PROPERTIES; WATER;

EID: 84867755100     PISSN: 07437463     EISSN: 15205827     Source Type: Journal    
DOI: 10.1021/la302281n     Document Type: Article

References (50)

1. Beaglehole, R.; Irwin, A.; Prentice, T. The World Health Report: 2004: Changing History; World Health Organization: Geneva, 2004.
2. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), 2011; http://www.ginasthma.org.
3. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Inititiative for Chronic Obstructive Lung Disease (GOLD), 2011; http://www.goldcopd.org.
4. Cazzola, M.; Gabriella Matera, M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study Respiratory Medicine 2007, 101 (5) 957-962
5. Newman, S. P. Principles of Metered-Dose Inhaler Design Respiratory Care 2005, 50 (9) 1177-1190
6. Wu, L.; da Rocha, S. R. P. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation Langmuir 2007, 23 (24) 12104-12110
7. Virchow, J.; Crompton, G.; Dal Negro, R.; Pedersen, S.; Magnan, A.; Seidenberg, J.; Barnes, P. Importance of inhaler devices in the management of airway disease Respiratory Medicine 2008, 102 (1) 10-19
8. Everard, M. L. Aerosol therapy past, present, and future: a clinician's perspective Respiratory Care 2000, 45 (6) 769
9. Rootmensen, G. N.; van Keimpema, A. R. J.; Jansen, H. M.; de Haan, R. J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method Journal of Aerosol Medicine and Pulmonary Drug Delivery 2010, 23 (5) 323-328
10. McFadden, E. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse Journal of Allergy and Clinical Immunology 1995, 96 (2) 278-283
11. Bell, J.; Newman, S. The rejuvenated pressurised metered dose inhaler Expert Opin. Drug Delivery 2007, 4, 215-234
12. Dolovich, M. A. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung Respiratory Care 2000, 45 (6) 597
13. Rogueda, P. Novel Hydrofluoroalkane Suspension Formulations for Respiratory Drug Delivery Exp. Opin. Drug Delivery 2005, 2 (4) 625-638
14. da Rocha, S. R. P.; Bharatwaj, B.; Saiprasad, S. Science and technology of pressurized metered-dose inhalers. In Controlled Pulmonary Drug Delivery, Smyth, H. D. C.; Hickey, A. J., Eds.; Springer: Berlin, 2011; pp 165-201.
15. Vervaet, C.; Byron, P. B. Drug-Surfactant-Propellant Interactions in HFA-Formulations Int. J. Pharm. 1999, 186, 13-30
16. Selvam, P.; Robson, P.; Chokshi, U.; da Rocha, S. R. P. Surfactant design for the 1,1,1,2-tetrafluoroethane-water interface: ab initio calculations and in situ high-pressure tensiometry Langmuir 2006, 22 (21) 8675-8683
17. Smyth, H. D. C. The influence of formulation variables on the performance of alternative propellant-driven metereddose inhalers Adv. Drug Delivery Rev. 2003, 55, 807-828
18. Michael, Y.; Snowden, M. J.; Chowdhry, B. Z.; Ashurst, I. C.; Davies-Cutting, C. J.; Riley, T. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system Int. J. Pharm. 2001, 221 (1-2) 165-174
19. Lechuga-Ballesteros, D.; Noga, B.; Vehring, R.; Cummings, R. H.; Dwivedi, S. K. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma Future Medicinal Chemistry 2011, 3 (13) 1703-1718
20. Cummings, R. H. Pressurized metered dose inhalers: Chlorofluorocarbon to hydrofluoroalkane transition-Valve performance Journal of Allergy and Clinical Immunology 1999, 104 (6) s230-s235
21. Traini, D.; Rogueda, P.; Young, P.; Price, R. Surface energy and interparticle force correlation in model pMDI formulations Pharm. Res. 2005, 22 (5) 816-825
22. Singh, G. J. P.; Poochikian, G., Development and Approval of Inhaled Respiratory Drugs: A US Regulatory Science Perspective. In Controlled Pulmonary Drug Delivery, Smyth, H. D. C.; Hickey, A. J., Eds.; Springer: New York, 2011; pp 489-527.
23. Purohit, D.; Trehan, A.; Arora, V. Development of room temperature stable formulation of formoterol fumarate/beclomethasone HFA pMDI Indian Journal of Pharmaceutical Sciences 2009, 71 (6) 713
24. Peguin, R. P. S.; Wu, L.; da Rocha, S. R. P. The ester group: How hydrofluoroalkane-philic is it? Langmuir 2007, 23 (16) 8291-8294
25. Steckel, H.; Wehle, S. A novel formulation technique for metered dose inhaler (MDI) suspensions Int. J. Pharm. 2004, 284 (1) 75-82
26. Engstrom, J. D.; Tam, J. M.; Miller, M. A.; Williams, R. O.; Johnston, K. P. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers Pharm. Res. 2009, 26 (1) 101-117
27. James, J.; Crean, B.; Davies, M.; Toon, R.; Jinks, P.; Roberts, C. J. The Surface Characterisation and Comparison of Two Potential Sub-Micron, Sugar Bulking Excipients for Use in Low-Dose, Suspension Formulations in Metered Dose Inhalers Int. J. Pharm. 2008, 361, 209-221
28. Wu, L.; da Rocha, S. Nanoparticle-stabilized Colloids in Compressible Hydrofluoroalkanes Langmuir 2011, 27, 10501-10506
29. Dellamary, L. A.; Tarara, T. E.; Smith, D. J.; Woelk, C. H.; Adractas, A.; Costello, M. L.; Gill, H.; Weers, J. G. Hollow Porous Particles in Metered Dose Inhalers Pharm. Res. 2000, 17 (2) 168-174
30. Vehring, R. Pharmaceutical Particle Engineering via Spray Drying Pharm. Res. 2008, 25 (5) 999-1022
31. Lechuga-Ballesteros, D.; Vehring, R.; Dwivedi, S. K. A New Cosuspension MDI Platform: Scientific Foundations of Mono, Dual and Triple Combination Products. In Respiratory Drug Delivery Europe, Dalby, R. N.; Byron, P. R.; Peart, J.; Suman, J. D.; Young, P. M., Eds.; Davis Healthcare International Publishing: River Grove, 2011; Vol. 1, pp 101-111.
32. Ivey, J.; Vehring, R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development Comput. Chem. Eng. 2010, 34 (7) 1030-1035
33. Cummings, R. H.; Joshi, V.; Lechuga-Ballesteros, D.; Flynn, B.; Vehring, R.; Schultz, R.; Noga, B.; Speck, J. H.; Dwivedi, S. K. Performance Advantages of Pearl Cosuspension Formulations Technology for Manufacturing of Metered-Dose Inhalers. In Respiratory Drug Delivery Europe, Dalby, R. N.; Byron, P. R.; Peart, J.; Suman, J. D.; Young, P. M., Eds.; Davis Healthcare International Publishing: River Grove, 2011; Vol. 2, pp 387-390.
34. Vehring, R.; Foss, W. R.; Lechuga-Ballesteros, D. Particle Formation in Spray Drying J. Aerosol Sci. 2007, 38 (7) 728-746
35. Tarara, T. E.; Hartman, M. S.; Gill, H.; Kennedy, A. A.; Weers, J. G. Characterization of Suspension-Based Metered Dose Inhaler Formulations Composed of Spray-Dried Budesonide Microcrystals Dispersed in HFA-134a Pharm. Res. 2004, 21 (9) 1607-1614
36. Chew, N. Y. K.; Tang, P.; Chan, H.-K.; Raper, J. A. How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders? Pharm. Res. 2005, 22 (1) 148-152
37. Weiler, C.; Egen, M.; Trunk, M.; Langguth, P. Force control and powder dispersibility of spray dried particles for inhalation J. Pharm. Sci. 2010, 99 (1) 303-316
38. Welte, T. Optimising treatment for COPD - new strategies for combination therapy International Journal of Clinical Practise 2009, 63 (8) 1136-1149
39. Welte, T.; Miravitlles, M.; Hernandez, P.; Eriksson, G.; Peterson, S.; Polanowski, T.; Kessler, R. Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine 2009, 180 (8) 741-750
40. Vehring, R.; Ivey, J.; Williams, L.; Joshi, V.; Dwivedi, S.; Lechuga-Ballesteros, D. In High-Sensitivity Analysis of Crystallinity in Respirable Powders Using Low Frequency Shift-Raman Spectroscopy, Respiratory Drug Delivery 2012, Dalby, R. N.; Byron, P. B.; Peart, J.; Suman, J. D.; Young, P. M., Eds.; Davis Healthcare International Publishing, 2012; pp 641-644.
41. Zhang, Y.; Finlay, W.; Matida, E. Particle deposition measurements and numerical simulation in a highly idealized mouth-throat J. Aerosol Sci. 2004, 35 (7) 789-803
42. Chambers, F.; Ludzik, A. In Vitro Drug Delivery Performance of a New Budesonide/Formoterol Pressurized Metered-Dose Inhaler Journal of Aerosol Medicine and Pulmonary Drug Delivery 2009, 22 (2) 113-120
43. Cyr, T.; Duhaime, R.; Graham, S.; Ormsby, E.; Lawrence, R.; LeBelle, M. Metered dose inhalers III: metaproterenol sulphate; particle size distribution and dose uniformity Journal of Pharmaceutical and Biomedical Analysis 1997, 15 (11) 1709-1718
44. Smyth, H. D. C. Propellant-driven metered-dose inhalers for pulmonary drug delivery Expert Opin. Drug Delivery 2005, 2 (1) 53-74
45. Cazzola, M.; Segreti, A.; Matera, M. G. Novel bronchodilators in asthma Current Opinion in Pulmonary Medicine 2010, 16 (1) 6
46. Noga, B.; Cummings, R. H.; Joshi, V.; Lechuga-Ballesteros, D.; Schultz, R.; Speck, J. H.; Dwivedi, S. Product Performance, Stability and Dose Proportionality of Glycopyrrolate Metered Dose Inhaler with Sub-Microgram Doses Using Cosuspension Technology. In Respiratory Drug Delivery, Dalby, R. N.; Byron, P. R.; Peart, J.; Suman, J. D.; Young, P. M., Eds.; Davis Healthcare International Publishing: River Grove, 2012; Vol. 2, pp 645-648.
47. Reisner, C.; Fogarty, C.; Spangenthal, S.; Dunn, L.; Kerwin, E. M.; Quinn, D.; Seale, J. P.; Thomas, M., St.; Rose, E.; Orevillo, C. J. Novel Combination Of Glycopyrrolate And Formoterol Mdi (gff-Mdi) Provides Superior Bronchodilation Compared To Its Components Administered Alone, Tiotropium Dpi, And Formoterol Dpi In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With COPD American Journal of Respiratory and Critical Care Medicine 2011, 183, A6435
48. Marjason, J.; Orevillo, C. J., St; Rose, E.; Ferguson, G. T.; Vehring, R.; Joshi, V.; Dwivedi, S.; Reisner, C. Assessment Of Safety And Pharmacokinetic Profile Of A Novel Fixed Combination Of Glycopyrrolate And Formoterol HFA MDI In Healthy Volunteers American Journal of Respiratory and Critical Care Medicine 2010, 181, A4455
49. Quinn, D.; Ferguson, G. T.; Orevillo, C. J.; Luckey, A.; St Rose, E.; Fischer, T.; Granko, H.; Reisner, C. A Novel Formoterol Fumarate Metered Dose Inhaler Formulation Demonstrates Comparable Bronchodilator Efficacy Relative To Foradil® Aerolizer® And Favorable Safety Outcomes In Patients With COPD American Journal of Respiratory and Critical Care Medicine 2010, 181, A4458
50. Rennard, S. I.; Fogarty, C.; Ferguson, G. T.; Orevillo, C. J., St; Rose, E.; Fischer, T.; Alameda, P.; Reisner, C. A Novel Glycopyrrolate Metered Dose Inhaler Formulation Demonstrates Superior Bronchodilator Efficacy Relative To Placebo And Comparable Efficacy And Safety To Spiriva® Handihaler® In Patients With COPD American Journal of Respiratory and Critical Care Medicine 2010, 181, A4450